Ok thanks, I like your line of thought. Obviously, you've seen some other class-action lawsuits play out.
My thought is, late next year, Lipocine will be more successful with no reverse splits and a higher share price, maybe a partner and a buy out.
What's your take on the 3rd CRL, can Tlando meet the criteria and get approval?
News 
Market Data 
Discover 
